# Palmitoleic Acid Combined With Infliximab for Promoting Intestinal Mucosal Healing in Crohn's Disease

> **NCT07417696** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Chinese Medical Association** · enrollment: 400 (estimated)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** Palmitoleic Acid + Infliximab
- **DRUG:** Infliximab

## Key facts

- **NCT ID:** NCT07417696
- **Lead sponsor:** Chinese Medical Association
- **Sponsor class:** NETWORK
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2029-03-31
- **Final completion:** 2029-03-31
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2026-02-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07417696

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07417696, "Palmitoleic Acid Combined With Infliximab for Promoting Intestinal Mucosal Healing in Crohn's Disease". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07417696. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*